Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Survival: N/R
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, New York
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 7/2002

Patients: Twenty-one patients with metastatic colorectal cancer were enrolled in this Phase II study. Twenty of the twenty-one patients had received prior 5-FU therapy and all twenty-one had received prior irinotecan therapy.

Treatment: Treatment comprised a new agent SCH 66336 which is a molecular inhibitor of Farnesyl protein transferase (FPTase). FPTase is an enzyme that is responsible for a critical post-translational modification of Ras.

Toxicity: Grade 3 toxicities included: diarrhea, fatigue, nausea, anemia, increased serum creatinine and increased bilirubin.

Results: There were no major objective responses.

Support: Two of the eleven authors of the study are affiliated with Schering-Plough Corporation.

Correspondence: Dr. S. Sharma

E-mail to a Friend Email Physician More Information